Study to Evaluate the Safety Tolerability and Preliminary Efficacy of XmAb 20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer
Enrolling By Invitation
18 years - 99 years
All
Phase
N/A
10 participants needed
1 Location
Brief description of study
The primary purposes of this research study are to determine the safety and tolerability of XmAb20717 by itself and in combination with other anticancer therapies. Subjects are being asked to take part in this research study because they have metastatic castration resistant prostate cancer (mCRPC), a prostate cancer that has spread beyond the prostate, and are no longer responding to hormone therapy.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: prostate cancer
-
Age: 18 years - 99 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 849699
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
